Literature DB >> 16286048

TaqMan RT-PCR and VERSANT HIV-1 RNA 3.0 (bDNA) assay Quantification of HIV-1 RNA viral load in breast milk.

Kiersten Israel-Ballard1, Rainer Ziermann, Christian Leutenegger, James Di Canzio, Kimmy Leung, Lynn Strom, Barbara Abrams, Caroline Chantry.   

Abstract

BACKGROUND: Transmission of HIV via breast milk is a primary cause of pediatric HIV infection in developing countries. Reliable methods to detect breast milk viral load are important.
OBJECTIVE: To correlate the ability of the VERSANT HIV 3.0 (bDNA) assay to real-time (RT) TaqMan PCR in quantifying breast milk HIV-1 RNA. STUDY
DESIGN: Forty-six breast milk samples that had been spiked with cell-free HIV-1 and eight samples spiked with cell-associated HIV-1 were assayed for HIV-1 RNA by both VERSANT HIV 3.0 and TaqMan RNA assays.
RESULTS: Only assays on the cell-free samples were statistically compared. Both a Deming regression slope and a Bland-Altman slope indicated a linear relationship between the two assays. TaqMan quantitations were on average 2.6 times higher than those of HIV 3.0. A linear relationship was observed between serial dilutions of spiked cell-free HIV-1 and both the VERSANT HIV 3.0 and the TaqMan RNA assays.
CONCLUSION: The two methods correlated well although the VERSANT HIV 3.0 research protocol quantified HIV-1 RNA slightly lower than TaqMan.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286048     DOI: 10.1016/j.jcv.2005.02.013

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

1.  Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Authors:  Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Authors:  Nancy M Archin; Rosalie Bateson; Manoj K Tripathy; Amanda M Crooks; Kuo-Hsiung Yang; Noelle P Dahl; Mary F Kearney; Elizabeth M Anderson; John M Coffin; Matthew C Strain; Douglas D Richman; Kevin R Robertson; Angela D Kashuba; Ronald J Bosch; Daria J Hazuda; Joann D Kuruc; Joseph J Eron; David M Margolis
Journal:  J Infect Dis       Date:  2014-03-11       Impact factor: 5.226

Review 3.  Mathematical Modeling of HIV Dynamics After Antiretroviral Therapy Initiation: A Review.

Authors:  Pablo S Rivadeneira; Claude H Moog; Guy-Bart Stan; Cecile Brunet; François Raffi; Virginie Ferré; Vicente Costanza; Marie J Mhawej; Federico Biafore; Djomangan A Ouattara; Damien Ernst; Raphael Fonteneau; Xiaohua Xia
Journal:  Biores Open Access       Date:  2014-10-01

4.  Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.

Authors:  Lisa Rahangdale; Kristina De Paris; Angela D M Kashuba; Julie A E Nelson; Mackenzie Cottrell; Craig Sykes; Cindi Emerson; Steven L Young; Trenton Stevens; Kristine B Patterson; Myron S Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

5.  Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal.

Authors:  Anne-Marie W Turner; Raghuvar Dronamraju; Frances Potjewyd; Katherine S James; Daniel K Winecoff; Jennifer L Kirchherr; Nancie M Archin; Edward P Browne; Brian D Strahl; David M Margolis; Lindsey I James
Journal:  ACS Infect Dis       Date:  2020-05-30       Impact factor: 5.084

6.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Authors:  N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

7.  In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.

Authors:  Perry Tsai; Guoxin Wu; Caroline E Baker; William O Thayer; Rae Ann Spagnuolo; Rosa Sanchez; Stephanie Barrett; Bonnie Howell; David Margolis; Daria J Hazuda; Nancie M Archin; J Victor Garcia
Journal:  Retrovirology       Date:  2016-05-21       Impact factor: 4.602

8.  Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.

Authors:  Cynthia L Gay; Joann D Kuruc; Shane D Falcinelli; Joanna A Warren; Sarah A Reifeis; Jennifer L Kirchherr; Katherine S James; Morgan G Dewey; Alyson Helms; Brigitte Allard; Erin Stuelke; Alicia Gamble; Ana Plachco; Robert J Gorelick; Joseph J Eron; Michael Hudgens; Carolina Garrido; Nilu Goonetilleke; Mark A DeBenedette; Irina Y Tcherepanova; Charles A Nicolette; Nancie M Archin; David M Margolis
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.